Jesus Guerra
Family · Mercedes, TXNPI 1558610477
Payments from drug & device makers
Across 164 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$567
- Lilly USA, LLC$431
- GSK$351
- Johnson & Johnson$265
- AstraZeneca$160
- Bayer$152
- plus $710 from 17 others
What the payments were for
- Food & beverage$2,636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $567 |
| Lilly USA, LLC | 34 | $431 |
| GSK | 22 | $351 |
| Johnson & Johnson | 13 | $265 |
| AstraZeneca | 11 | $160 |
| Bayer | 8 | $152 |
| Abbott | 6 | $110 |
| Boehringer Ingelheim | 5 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Exact Sciences | 3 | $57 |
| Pfizer | 4 | $57 |
| Astellas Pharma US Inc | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| AbbVie | 2 | $38 |
| Amgen | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Novartis | 2 | $28 |
| Averitas Pharma Inc. | 1 | $26 |
| Phadia US Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Merck | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Optinose US, Inc. | 1 | $11 |
How this compares
$2,636 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 170 | $175,121 |
| JardianceEmpagliflozin | 87 | $125,975 |
| OzempicSemaglutide | 89 | $106,594 |
| TrulicityDulaglutide | 48 | $73,998 |
| XareltoRivaroxaban | 62 | $72,344 |
| RybelsusSemaglutide | 42 | $52,738 |
| LinzessLinaclotide | 56 | $44,139 |
| EliquisApixaban | 38 | $43,988 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $30,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $29,865 |
| MyrbetriqMirabegron | 39 | $28,968 |
| JanuviaSitagliptin Phosphate | 17 | $24,366 |
| VascepaIcosapent Ethyl | 37 | $22,392 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $22,147 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $14,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $160 | $175,121170 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $84 | $169,141124 claims |
| Novo NordiskOzempic, Rybelsus | $567 | $159,331131 claims |
| Lilly USA, LLCTrulicity | $431 | $73,99848 claims |
| Johnson & JohnsonXarelto | $265 | $72,34462 claims |
| AbbVieLinzess | $38 | $44,13956 claims |
| PfizerEliquis | $57 | $43,98838 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $351 | $38,04561 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $28,96839 claims |
| MerckJanuvia | $16 | $24,36617 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $74 | $9,79814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Mercedes
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.